Market Analysis and Price Projections for NDC: 16571-0834 (Amantadine Hydrochloride)
Introduction
Amantadine Hydrochloride, with the NDC code 16571-0834, is a medication manufactured by Rising Pharma Holdings, Inc. This drug is used primarily for the treatment of Parkinson's disease, drug-induced extrapyramidal reactions, and influenza A virus infections. Here, we will delve into the market analysis and price projections for this medication.
Current Market Context
The pharmaceutical market, particularly for generic drugs like Amantadine Hydrochloride, is influenced by several factors including regulatory changes, market competition, and healthcare policies.
Regulatory Environment
The Medicare Drug Price Negotiation Program, initiated under the Inflation Reduction Act, aims to reduce prescription drug costs for Medicare beneficiaries. Although Amantadine Hydrochloride is not among the first 10 drugs selected for negotiation in 2026, the broader impact of this program on the pharmaceutical industry could indirectly affect its pricing[2][5].
Price Trends and Projections
Historical Price Changes
Historically, prescription drug prices in the U.S. have seen significant increases. For instance, between 2018 and 2023, many drugs experienced list price increases ranging from 20% to 55%[2]. However, generic drugs like Amantadine Hydrochloride tend to have more stable pricing due to market competition.
Current Pricing
As of the latest data, the pricing for Amantadine Hydrochloride is not subject to the same level of negotiation as the drugs selected under the Medicare Drug Price Negotiation Program. The Wholesale Acquisition Cost (WAC) or list price for generic drugs is generally lower and more stable compared to brand-name drugs[2].
Future Projections
Given the generic nature of Amantadine Hydrochloride, future price projections are likely to remain relatively stable. Here are a few key points to consider:
- Market Competition: The presence of multiple manufacturers for generic Amantadine Hydrochloride helps keep prices competitive and stable.
- Regulatory Impact: While not directly affected by the Medicare Drug Price Negotiation Program, any broader regulatory changes aimed at reducing drug prices could have a ripple effect on the market.
- Economic Factors: Economic conditions, such as inflation and supply chain costs, can influence the pricing of pharmaceuticals. However, generic drugs are generally less susceptible to large price swings.
Impact of Medicare Drug Price Negotiation Program
Although Amantadine Hydrochloride is not among the drugs selected for the first cycle of negotiations, the program's overall impact on the pharmaceutical industry could lead to a more price-sensitive market. Here are some key points:
- Negotiated Prices: The program has resulted in significant discounts for selected drugs, ranging from 38% to 79% compared to list prices. This could set a precedent for future negotiations and influence the pricing strategies of pharmaceutical companies[2][5].
- Broader Market Effects: The success of the negotiation program could lead to increased pressure on pharmaceutical companies to cap price increases, potentially benefiting a wider range of medications, including generics like Amantadine Hydrochloride.
Factors Driving Price Changes
Several factors contribute to the pricing dynamics of pharmaceuticals, including:
Intellectual Property and Exclusivity
For generic drugs, the absence of patent protection means that multiple manufacturers can produce the drug, leading to competitive pricing[3].
Supply and Demand
Changes in supply and demand can affect prices. However, for a widely used drug like Amantadine Hydrochloride, the demand is generally consistent, and supply is maintained by multiple manufacturers.
Unusual Dosage Forms and Limited Distribution
These factors can lead to extraordinary price increases, but they are less relevant for a standard generic medication like Amantadine Hydrochloride[3].
Illustrative Statistics
- Price Stability: Generic drugs typically experience less than 10% annual price changes, unlike brand-name drugs which can see increases of 20% to 55% over a few years[2].
- Market Share: The total Part D gross covered prescription drug costs for the first cycle of negotiated drugs in 2023 were $56.2 billion, highlighting the significant impact of pricing on healthcare expenditure[2].
Expert Insights
Industry experts often highlight the importance of competition and regulatory oversight in maintaining stable and affordable drug prices.
"The presence of multiple generic manufacturers helps to keep prices competitive and stable, which is beneficial for patients and healthcare systems alike."[4]
Key Takeaways
- Stable Pricing: Amantadine Hydrochloride, as a generic drug, is expected to maintain relatively stable pricing due to market competition.
- Regulatory Impact: Broader regulatory changes, such as the Medicare Drug Price Negotiation Program, could indirectly influence the pricing dynamics of generic drugs.
- Economic and Market Factors: Economic conditions and market competition will continue to play a significant role in determining the prices of generic medications.
FAQs
Q: What is the NDC code for Amantadine Hydrochloride manufactured by Rising Pharma Holdings, Inc.?
A: The NDC code is 16571-0834.
Q: Is Amantadine Hydrochloride subject to the Medicare Drug Price Negotiation Program?
A: No, it is not among the first 10 drugs selected for negotiation in 2026.
Q: What factors influence the pricing of generic drugs like Amantadine Hydrochloride?
A: Market competition, regulatory changes, and economic factors such as inflation and supply chain costs.
Q: How do regulatory changes impact the pricing of pharmaceuticals?
A: Regulatory changes, such as the Medicare Drug Price Negotiation Program, can lead to more competitive pricing and reduced price increases.
Q: What is the expected price stability for Amantadine Hydrochloride in the future?
A: The price is expected to remain relatively stable due to market competition and the generic nature of the drug.
Cited Sources
- Find-A-Code: Rising Pharma Holdings, Inc. - List of Drugs.
- ASPE - HHS.gov: Medicare Drug Price Negotiation Program.
- S&P Global: New Study Indicates "Extraordinary" Price Rises in 17 Drugs in U.S.
- DailyMed: Label: DICLOFENAC SODIUM tablet, delayed release.
- CMS: Fact Sheet: Negotiated Prices Initial Price Applicability Year 2026.
